Exploring Edgewise Therapeutics, Inc. (EWTX) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Edgewise Therapeutics Inc. (EWTX), a biopharmaceutical company focusing on muscle disease therapeutics? Have you ever wondered who the major players are behind the scenes, influencing its trajectory in the market? As of April 2025, 413 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 107,777,231 shares. With recent financial disclosures showing a Q4 operating expense of $45.5 million and a net loss of $0.42 per share, understanding the investor landscape becomes even more crucial. Let's delve into the key institutional investors and insiders who are shaping the future of Edgewise Therapeutics, and explore the potential reasons behind their investment decisions.

Edgewise Therapeutics, Inc. (EWTX) Who Invests in Edgewise Therapeutics, Inc. (EWTX) and Why?

Understanding the investor profile of Edgewise Therapeutics, Inc. (EWTX) involves examining the diverse range of entities and individuals who hold its stock, along with their motivations and strategies. This insight is crucial for gauging market sentiment and potential stock performance.

Key investor types in Edgewise Therapeutics, Inc. (EWTX) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts. Their investment decisions are often influenced by factors such as personal financial goals, risk tolerance, and information gathered from various sources.
• Institutional Investors: These are organizations that invest on behalf of others and include:
  • Mutual Funds: Pools of money collected from many investors to invest in a diversified portfolio of securities.
  • Hedge Funds: Investment partnerships that use more aggressive strategies to generate higher returns.
  • Pension Funds: Funds that provide retirement income to employees.
  • Insurance Companies: Firms that invest premiums to cover future claims.
  • Endowments: Funds established to support ongoing charitable activities.
• Corporate Insiders: Company executives and board members who own shares in Edgewise Therapeutics, Inc. (EWTX). Their transactions are closely monitored as they can provide insights into the company's prospects.

Several factors attract investors to Edgewise Therapeutics, Inc. (EWTX):

• Growth Prospects: Investors are often drawn to Edgewise Therapeutics, Inc. (EWTX) due to its potential for significant growth. This could be driven by factors such as:
  • Pipeline Development: Progress in developing and commercializing new treatments.
  • Market Expansion: Opportunities to enter new markets or expand its product offerings.
  • Strategic Partnerships: Collaborations with other companies that can enhance its capabilities and market reach.
• Market Position: Edgewise Therapeutics, Inc. (EWTX)'s standing in the biotechnology industry influences investor confidence. A strong market position can be based on:
  • Competitive Advantages: Unique technologies, patents, or expertise that set it apart from competitors.
  • Brand Reputation: A positive image and strong relationships with healthcare providers and patients.
  • Market Share: A significant portion of the market for its products.

Investors in Edgewise Therapeutics, Inc. (EWTX) adopt various strategies depending on their investment goals and risk tolerance:

• Long-Term Holding: Some investors buy shares with the intention of holding them for an extended period, aiming to benefit from the company's long-term growth.
• Short-Term Trading: Other investors engage in more frequent trading, seeking to profit from short-term price fluctuations.
• Value Investing: Value investors look for companies that they believe are undervalued by the market, with the expectation that their stock price will eventually reflect their intrinsic value.

For more insights into Edgewise Therapeutics, Inc. (EWTX), consider exploring their Mission Statement, Vision, & Core Values of Edgewise Therapeutics, Inc. (EWTX).

Edgewise Therapeutics, Inc. (EWTX) Institutional Ownership and Major Shareholders of Edgewise Therapeutics, Inc. (EWTX)

Understanding the institutional ownership of Edgewise Therapeutics, Inc. (EWTX) provides valuable insights into the company's investor profile and market sentiment. Institutional investors, such as mutual funds, hedge funds, and pension funds, often hold significant stakes in publicly traded companies, and their investment decisions can influence a company's stock price and overall strategy. Examining the major shareholders and their recent activity can reveal trends in investor confidence and potential future performance.

Here's an overview of Edgewise Therapeutics, Inc. (EWTX)'s institutional ownership, changes in ownership, and the impact of these large investors:

• Top Institutional Investors: A list of the largest institutional investors and their shareholdings in Edgewise Therapeutics, Inc. (EWTX).
• Changes in Ownership: Information on whether institutional investors have increased or decreased their stakes recently.
• Impact of Institutional Investors: An analysis of the role these large investors play in the company’s stock price and strategy.

As of 2024, the top institutional investors in Edgewise Therapeutics, Inc. (EWTX) and their approximate holdings are:

• Fidelity Management & Research Co: Holding a significant number of shares, reflecting a strong belief in the company’s potential.
• BlackRock Fund Advisors: Another major holder, indicating broad institutional interest.
• Vanguard Group Inc: Holding a notable percentage, showcasing confidence in the company’s long-term prospects.
• RA Capital Management, L.P.: A key investor with substantial holdings.
• State Street Global Advisors, Inc.: Maintaining a considerable position in the company.

These major institutional players collectively hold a substantial portion of Edgewise Therapeutics, Inc. (EWTX)'s outstanding shares. Their investment decisions are often based on in-depth research and analysis, signaling confidence in the company's business model, pipeline, and growth opportunities.

Analyzing recent changes in ownership provides insights into the evolving sentiment of institutional investors. Increases in holdings may indicate growing confidence in Edgewise Therapeutics, Inc. (EWTX)’s prospects, while decreases may suggest concerns or shifting investment strategies. For instance, if a major institutional investor like Fidelity or BlackRock increases its stake, it often signals positive expectations for the company's future performance.

The presence and activity of large institutional investors can have a significant impact on Edgewise Therapeutics, Inc. (EWTX)'s stock price and overall strategy:

• Stock Price Stability: Institutional investors often provide a level of stability to the stock price due to their large holdings and long-term investment horizons.
• Increased Liquidity: Higher institutional ownership typically leads to increased trading volume and liquidity in the stock.
• Strategic Influence: Major shareholders can influence corporate strategy through voting rights and engagement with management.
• Market Confidence: The presence of reputable institutional investors can enhance market confidence and attract additional investors.

Institutional investors play a crucial role in the financial ecosystem of Edgewise Therapeutics, Inc. (EWTX). Their investment decisions, driven by thorough research and analysis, can significantly influence the company's stock price, market perception, and strategic direction. Monitoring these investors and their activities provides valuable insights for anyone looking to understand the dynamics of Edgewise Therapeutics, Inc. (EWTX) in the market.

To gain a broader understanding of Edgewise Therapeutics, Inc. (EWTX)'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Edgewise Therapeutics, Inc. (EWTX).

Edgewise Therapeutics, Inc. (EWTX) Key Investors and Their Impact on [Company Name]

Edgewise Therapeutics, Inc. (EWTX) has a diverse investor base, primarily composed of institutional investors. As of April 2025, 413 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 107,777,231 shares.

Here's a breakdown of key aspects regarding Edgewise Therapeutics' investors:

• Notable Investors: Major shareholders include:
  • Orbimed Advisors LLC with 15.78% hold, 15,021,721 shares and a value of $202.04M
  • RA Capital Management, L.P.
  • BlackRock, Inc.
  • Baker Bros. Advisors LP
  • Novo Holdings A/S
  • Janus Henderson Group PLC
  • Paradigm Biocapital Advisors LP
  • Vanguard Group Inc
  • Cormorant Asset Management, LP
  • Perceptive Advisors Llc
• Investor Influence: Institutional ownership accounts for a significant portion of Edgewise Therapeutics' shares. These major holders can influence company decisions and stock movements. Specifically, a Schedule 13D filing indicates that an investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.
• Recent Moves:
  • On April 2, 2025, Edgewise Therapeutics announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at $20.13 per share, resulting in gross proceeds of approximately $200 million.
  • The deal included participation from various funds such as Braidwell LP, Cormorant Asset Management, Driehaus Capital Management, Invus, Janus Henderson Investors, MPM BioImpact, OrbiMed, Paradigm BioCapital Advisors, Perceptive Advisors, RA Capital Management and Sofinnova Investments, Inc.
  • Edgewise intends to use the net proceeds to support the potential U.S. commercial launch of sevasemten in patients with Becker muscular dystrophy, advancement of Phase 3 trials, and other research and development programs.

Recent insider activity shows a net buying trend over the last 3 and 12 months:

• In the last 3 months, the number of shares bought by insiders was 994,101, while the number of shares sold was 54,051, resulting in a net activity of 940,050 shares.
• Over the past 12 months, insiders bought 994,101 shares and sold 518,245 shares, with a net activity of 475,856 shares.

The institutional ownership structure of Edgewise Therapeutics shows current positions in the company by institutions and funds, as well as latest changes in position size.

The share price as of April 17, 2025, was $13.45 per share, compared to $15.45 per share on April 18, 2024. This represents a decline of 12.94% over that period.

Here is a table summarizing the top 10 institutional shareholders of Edgewise Therapeutics, Inc. (EWTX):

Understanding the investor profile of Edgewise Therapeutics can provide insights into the company's stability, growth potential, and strategic direction. For more insights into the company's goals, vision, and values, check out Mission Statement, Vision, & Core Values of Edgewise Therapeutics, Inc. (EWTX).

Edgewise Therapeutics, Inc. (EWTX) Market Impact and Investor Sentiment

Investor sentiment and market reactions significantly influence Edgewise Therapeutics, Inc. (EWTX). Understanding these dynamics provides insights into the company's stock performance and future prospects. Here's an overview of investor sentiment, recent market reactions, and analyst perspectives regarding Edgewise Therapeutics, Inc. (EWTX).

Investor Sentiment:

The prevailing sentiment among major shareholders reflects their confidence in Edgewise Therapeutics, Inc. (EWTX). Analyzing recent trading patterns and ownership changes helps gauge whether the sentiment is positive, neutral, or negative.

• Positive Sentiment: Increased buying activity and long-term holdings by institutional investors often indicate a positive outlook.
• Neutral Sentiment: Stable ownership percentages and moderate trading volumes may suggest a neutral stance, where investors are neither aggressively buying nor selling.
• Negative Sentiment: Significant sell-offs or decreased institutional ownership could signal concerns about the company's performance or future prospects.

As of the latest data, key institutional investors and their recent activities include:

• Vanguard Group Inc.: Holds 3,278,528 shares, representing 7.11% of the company.
• BlackRock Inc.: Holds 2,392,571 shares, accounting for 5.18% of the company.
• State Street Corp: Holds 1,274,982 shares, which is 2.76% of the company.
• FMR LLC: Holds 1,190,909 shares, representing 2.58% of the company.
• RA Capital Management, L.P.: Holds 1,051,000 shares, accounting for 2.28% of the company.

Recent Market Reactions:

The stock market's response to changes in ownership or large investor moves provides valuable insights into market confidence. Significant investments or divestments by major shareholders often trigger noticeable stock price movements.

• Positive Reactions: Announcements of increased stakes by reputable investors can lead to a surge in stock prices, reflecting increased market confidence.
• Negative Reactions: Large-scale sell-offs or reports of decreased institutional ownership may result in a stock price decline, signaling investor concerns.

Analyst Perspectives:

Financial analysts play a crucial role in interpreting the impact of key investors on Edgewise Therapeutics, Inc. (EWTX)'s future. Their insights often influence investor sentiment and market behavior.

• Positive Outlook: Analysts may highlight the strategic benefits of having strong institutional backing, such as increased financial stability and access to resources.
• Neutral Stance: Some analysts might focus on the company's fundamentals, irrespective of investor movements, emphasizing the importance of clinical trial outcomes and market potential.
• Cautious View: Analysts may express concerns if there are significant shifts in investor composition, especially if it involves the departure of long-term, strategic investors.

According to recent analyst ratings:

• As of April 15, 2024, the consensus rating for Edgewise Therapeutics, Inc. (EWTX) is a 'Buy.'
• The average price target is $25.67, suggesting a potential upside.

Ownership Summary:

Understanding the ownership structure of Edgewise Therapeutics, Inc. (EWTX) provides additional context for assessing market impact and investor sentiment.

The high percentage of institutional ownership indicates strong confidence from major financial institutions. Meanwhile, insider ownership reflects the alignment of interests between the company's management and its shareholders.

For more detailed information on the company's background, mission, and ownership structure, you can refer to: Edgewise Therapeutics, Inc. (EWTX): History, Ownership, Mission, How It Works & Makes Money